Cumulative drug approval applications under priority review (annual)

Since China updated its drug registration and administrative rules in 2020, 496 drug approval applications have been placed under the priority review program, with 42.54 percent treating cancer.

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA

National Medical Products Administration. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Via StatOrigin, https://statorigin.org/stat/stat_K4TT8DNWNY5FFD4SR1X56F0PT1

Copy

MLA

National Medical Products Administration. "Measures facilitate approval of 48 first-in-class innovative drugs." 2024, https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Accessed 17 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_K4TT8DNWNY5FFD4SR1X56F0PT1.

Copy

Chicago

National Medical Products Administration. "Measures facilitate approval of 48 first-in-class innovative drugs." 2024. https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Accessed September 17, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_K4TT8DNWNY5FFD4SR1X56F0PT1.

Copy

BibTeX

@misc{nmpa2024cumulative6f0pt1, author = {{National Medical Products Administration}}, title = {Measures facilitate approval of 48 first-in-class innovative drugs}, year = {2024}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_K4TT8DNWNY5FFD4SR1X56F0PT1}, note = {Original source: https://english.nmpa.gov.cn/2025-03/21/c\_1080286.htm. Accessed September 17, 2026.} }

Copy

Everything needed to check this number yourself, without taking our word for it.

Record last modified 17 September 2026. Value type: actual. Update cadence: annual. This page is permanently addressable at statorigin.org/stat/stat_K4TT8DNWNY5FFD4SR1X56F0PT1.